Patients deserve agency over their own bodies and care, and clinicians, educators, and caregivers can be those catalysts needed to promote disability rights in healthcare practices across the industry.
BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of the commercial launch of Roctavian, the first FDA-approved hemophilia A gene therapy.
Jona, a New York-based gut microbiome testing startup, emerged from stealth with $5 million in funding. The company's at-home microbiome profiling kit educates users about how the community of microorganisms residing in their gut impacts their overall health. The platform also offers recommendations concerning diet and lifestyle modifications based on users’ personal health goals.
BeMe Health, a digital mental health company for teens, is teaming up with Inland Empire Health Plan and Molina Healthcare of California to bring BeMe's platform to 10 local educational agencies. The partnership will support more than 72,000 teens.
Eli Lilly is acquiring Beam Therapeutics’ opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve gene-editing therapy for a different target.